Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Subspecialties Cataract, Basic & Translational Research, Business and Innovation, Other

Clearing the Path

Credit: Images by Aleksandra Jones.

We all know that life has its inevitabilities (try not to think of death and taxes), but does surgical intervention in cataract treatment need to be one of them? Researchers have recently been exploring the effects of topically administered oxysterol compounds on the optics of the lens. Oxysterol compounds have previously been found to interact with proteins essential for lens transparency, and as a result have been touted as potential anti-cataracts drugs.

As Barbara Pierscionek, Deputy Dean of Research and Innovation a the Anglia Ruskin University, Chelmsford, UK, and leader of the international group of scientists conducting the study, explains, “The structural effect of oxysterol compounds on the lens have been examined in the past, but their effect on the functional aspects, the optics, which are critical to vision, have not been considered.” In this pioneering study, the researchers observed that treating a murine model of cataracts with the oxysterol compound VP1-001 resulted in an improvement in refractive index profiles in the majority of lenses and a reduction in the lens opacity in nearly half of all cases (1).

Yes, the results have only been shown in mice, but there’s no denying the hope – even promise – of a simpler, less invasive alternative to surgery. And Pierscionek and her team will continue to pursue that very goal. “We will continue to investigate VP1-001 and other compounds to determine which are the most effective for treating the different forms of cataracts,” she says. “I would like to see [our work] improve the treatments offered for cataracts globally and, in particular, those offered in developing countries, helping those who lack access to current surgery or care.”

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. K Wang et al., Invest Ophthalmol Vis Sci., 63, 15 (2022), PMID: 35575904.
About the Author
Jed Boye

Associate Editor, The Ophthalmologist

I have always been fascinated by stories. During my biomedical sciences degree, though I enjoyed wet lab sessions, I was truly in my element when sitting down to write up my results and find the stories within the data. Working at Texere gives me the opportunity to delve into a plethora of interesting stories, sharing them with a wide audience as I go.

Related Case Study
Uncovering Ocular Comorbidity

| Contributed by Quidel

Related Product Profiles
Sulcus-based enhancement of visual quality

| Contributed by Medicontur Medical Engineering Ltd

Less Steps, More Vision

| Contributed by Medicontur Medical Engineering Ltd

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Here
Most Popular
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register